Henry Ji - Sorrento Therape Co-Founder, CEO and President and Director
| SRNE Stock | USD 0 0.0005 16.67% |
CEO
Dr. Henry Ji, Ph.D., is the President, Chief Executive Officer, Director of Sorrento Therapeutics Inc. He cofounded and has served as a director of Sorrento Therapeutics, Inc. since January 2006, served as its Chief Scientific Officer from November 2008 to September 2012, as its Interim Chief Executive Officer from April 2011 to September 2012, and as its Chief Executive Officer and President since September 2012. Dr. Ji also served as our Secretary from September 2009 to June 2011. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporationrationration, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji cofounded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporationrationration, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento Therapeutics Inc.s intellectual property since 2012.
| Age | 60 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 858 203 4100 |
| Web | https://www.sorrentotherapeutics.com |
Henry Ji Latest Insider Activity
Tracking and analyzing the buying and selling activities of Henry Ji against Sorrento Therape otc stock is an integral part of due diligence when investing in Sorrento Therape. Henry Ji insider activity provides valuable insight into whether Sorrento Therape is net buyers or sellers over its current business cycle. Note, Sorrento Therape insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sorrento Therape'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Henry Ji over three weeks ago Disposition of tradable shares by Henry Ji of Sorrento Therape subject to Rule 16b-3 | ||
Henry Ji over a month ago Acquisition by Henry Ji of 200000 shares of Scilex Holding at 1.41 subject to Rule 16b-3 | ||
Henry Ji over three months ago Acquisition by Henry Ji of 10000 shares of Sorrento Therape at 4.0 subject to Rule 16b-3 | ||
Henry Ji over six months ago Disposition of tradable shares by Henry Ji of Scilex Holding subject to Rule 16b-3 |
Sorrento Therape Management Efficiency
The company has return on total asset (ROA) of (0.4082) % which means that it has lost $0.4082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.7892) %, meaning that it created substantial loss on money invested by shareholders. Sorrento Therape's management efficiency ratios could be used to measure how well Sorrento Therape manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CEO Age | ||
| Tsutomu Takemura | Nomura Holdings ADR | N/A | |
| Dr DES | Globalfoundries | 65 | |
| Kunio Watanabe | Nomura Holdings ADR | 56 | |
| Gideon BenZvi | Valens | 64 | |
| Koji Nagai | Nomura Holdings ADR | 60 | |
| Jonathan Lewis | Nomura Holdings ADR | N/A | |
| Kentaro Okuda | Nomura Holdings ADR | 61 | |
| Adaire FoxMartin | Equinix | 60 | |
| Yo Akatsuka | Nomura Holdings ADR | N/A | |
Management Performance
| Return On Equity | -3.79 | |||
| Return On Asset | -0.41 |
Sorrento Therape Leadership Team
Elected by the shareholders, the Sorrento Therape's board of directors comprises two types of representatives: Sorrento Therape inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sorrento. The board's role is to monitor Sorrento Therape's management team and ensure that shareholders' interests are well served. Sorrento Therape's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sorrento Therape's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Brunswick, VP Affairs | ||
| Scott Schaus, Chief Officer | ||
| Xiao MD, Pres ACEA | ||
| Robert Allen, VP RD | ||
| Brian Cooley, Sr BU | ||
| Shawn Sahebi, VP Operations | ||
| Henry Ji, Co-Founder, CEO and President and Director | ||
| Alexis DVM, VP BU | ||
| William BSc, VP Devel | ||
| Elizabeth MBA, CFO VP | ||
| JD MD, SVP Officer |
Sorrento Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Sorrento Therape a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.79 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (5.11) % | |||
| Current Valuation | 129.17 M | |||
| Shares Outstanding | 551.28 M | |||
| Shares Owned By Insiders | 0.80 % | |||
| Shares Owned By Institutions | 0.03 % | |||
| Number Of Shares Shorted | 64.56 M | |||
| Price To Earning | 41.15 X | |||
| Price To Book | 4.01 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Sorrento OTC Stock
Sorrento Therape financial ratios help investors to determine whether Sorrento OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sorrento with respect to the benefits of owning Sorrento Therape security.